Medicamen Biotech Limited — Important, 08-04-2025: General Updates

Medicamen has signed a distribution agreement with XGX Pharma in Denmark for three products aimed at the European market. The agreement includes the Marketing Authorization for two oncology products—Temozolamide capsules (250 mg) and Bortozemib (3.5 mg injection)—alongside Amoxicillin oral dispersible tablets (250 mg), a Beta-lactam antibiotic. This strategic tie-up enhances Medicamen's footprint in the European pharmaceutical sector, potentially driving revenue growth. Investors should watch closely for the impact of these products on the company's market position and overall performance.